The striking anti-neuroinflammatory and neuroprotective effects of PPARg agonists have led to the recent initiation of pioglitazone, a PPARg agonist that crosses the blood brain barrier, to either treat or delay the progression of a variety of neurodegenerative diseases including Alzheimer’s disease [74,75], Parkinson’s disease [75], Huntington’s disease [75], Friedrichs’ ataxia [75], and the demyelination of multiple sclerosis [75]. This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.